Hematopoietic System Diseases

The European Medicines Agency has recommended Fabhalta for treating paroxysmal nocturnal hemoglobinuria after reviewing clinical trial results.

Cases occurred in the wake of record-breaking heat waves

Newborns should be diagnosed 'super early' and receive ART in maternity ward, experts say

TALZENNA is first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer (mCRPC) Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in…

After having her concerns dismissed by her doctor, a woman diagnosed with Hodgkin lymphoma partnered with the Lymphoma Research Foundation to spread the word about unique challenges facing patients.

A large US analysis found that this newly discovered genetic disease has an estimated prevalence of 1 in 4269 in men older than 50.

NIH-funded researchers complete first study comparing commonly used type 2 diabetes medications.

For the second straight day, the FDA's Cellular, Tissue and Gene Therapies adcomm voted unanimously in favor of FDA approving a bluebird bio gene therapy, this time by a 13-0 vote in favor of beti-cel as a potential treatment for a blood disorder known as β-thalassemia for those who require

An Australian man credited with saving more than 2 million babies through decades of regular blood and plasma donations has died at age 88.

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being developed.

NIH-supported study shows long-term benefits of surgery compared to medication and lifestyle change.

But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert

The only cure for painful sickle cell disease today is a bone marrow transplant. On Tuesday, advisers to the Food and Drug Administration will review a gene...

Aggressive treatment may still be an option

The X-linked syndrome is a systemic autoinflammatory disease of undefined origin. It resists the classic therapeutic arsenal, but Janus kinase pathway inhibitors show promise as treatments.

The company has applied for approval of beti-cel as a one-time gene therapy for the treatment of Beta-thalassemia patients dependent on blood transfusions. ...

VA data found increased risk of post-COVID symptoms among those with breakthrough infections

Gene therapy is also emerging as a promising alternative

New research led by NHS Blood and Transplant scientists establishes a new blood group system, MAL, as home to the AnWj antigen.

VERIFIED A study published in JAMA Oncology reported that MRD-negative status assessed by flow cytometry was associated with acute lymphoblastic